to Accelerate Central Nervous System Research.
August 29, 2024 – Lyon, France and Bordeaux, France – Cynbiose, a leading preclinical contract research organisation (CRO) specialised in non-human primate (NHP) models, and Motac Neuroscience, a pioneer in neurodegenerative disease research and drug development, are pleased to announce a strategic partnership aimed at accelerating the development of novel therapeutics for central nervous system diseases.
Hugues Contamin CEO Cynbiose
« We are thrilled to partner with Motac Neuroscience, a leader in neurodegenerative research. This collaboration underscores our commitment to advancing scientific knowledge and developing effective therapies for these devastating diseases, » said Dr. Hugues Contamin, CEO of Cynbiose. « By combining our expertise, we can significantly enhance the preclinical development process to and bring hope to patients faster. »
Erwan Bezard CEO MOTAC
« Our partnership with Cynbiose marks a significant milestone in our mission to develop groundbreaking treatments for neurodegenerative diseases, » said Dr. Erwan Bezard, CSO of Motac Neuroscience. « Cynbiose’s unparalleled expertise in NHP models will be instrumental in validating our research and advancing promising candidates to the next stage of development. »